Hedging Your Bets Ahead of Amgen v Sanofi: Anticipating How the Supreme Court’s Enablement Ruling Will Affect Biologic Patent Portfolio Strategies
Maureen A. Bresnahan
Assistant General Counsel
Eisai Inc.
Ivan M. Poullaos
Partner
Winston & Strawn LLP
Daniel Margolis
Partner
Allen & Overy LLP
John J. Molenda
Partner
Steptoe & Johnson LLP
Jason Murata
Partner
Axinn, Veltrop & Harkrider LLP
- Devising alternate strategies for drafting enforceable claims
- Outlining the scope of appropriate claims for antibodies
- Implementing new strategies for drafting enforceable claims in view of the Supreme Court’s decision
- Understanding the nuances between written description and enablement
- Why did the Supreme Court decline to hear Kite v Juno?
- Reconciling whether written description is met when the specification discloses formulas